Pealkiri: 

Variation in "standard care" for breast cancer across Europe: a EUROCARE-3 high resolution study

Autorid: Allemani C , Storm H , Voogd AC , Holli K , Izarzugaza I , Torrella-Ramos A , Belska-Lasota M , Aareleid T , Ardanaz E , Colonna M , Crocetti E , Danzon A , Federico M , Garau I , Grosclaude P , Hedelin G , Martinez-Carcia C , Peignaux K , Plesko I , Primic-Zakelj M , Rachtan J , Tabliabue G , Tumino R , Traina A , Tryggvadottir L , Vercelli M , Sant M
Väljaandja/tellija: European Journal of Cancer
Märksõnad: kasvajad, patsiendid, ravi, Euroopa
Välja antud: 2010
Tüüp: Teaduslik artikkel/kogumik
Viide: Allemani C, Storm H, Voogd AC, et al. Variation in "standard care" for breast cancer across Europe: a EUROCARE-3 high resolution study. European Journal of Cancer 2010;46(9):1528-36.
Link: http://www.ejcancer.info/article/S0959-8049%2810%2900119-X/abstract
Alamvaldkonnad:Terviseteenuste korraldus, kättesaadavus ja kvaliteet
Mittenakkushaigused
Kirjeldus: On a population-based sample of 13,500 European breast cancer patients mostly diagnosed in 1996-1998 and archived by 26 cancer registries, we used logistic regression to estimate odds of conservative surgery plus radiotherapy (BCS + RT) versus other surgery, in T1N0M0 cases by country, adjusted for age and tumour size. We also examined: BCS + RT in relation to total national expenditure on health (TNEH); chemotherapy use in N+ patients; tamoxifen use in oestrogen positive patients; and whether P10 nodes were examined in lymphadenectomies. Stage, diagnostic examinations and treatments were obtained from clinical records.
1N0M0 cases were 33.0% of the total. 55.0% of T1N0M0 received BCS + RT, range 9.0% (Estonia) to 78.0% (France). Compared to France, odds of BCS + RT were lower in all other countries, even after adjusting for covariates. Women of 70-99 years had 67% lower odds of BCS + RT than women of 15-39 years. BCS + RT was 20% in low TNEH, 58% in medium TNEH, and 64% in high TNEH countries. Chemotherapy was given to 63.0% of N+ and 90.7% of premenopausal N+ (15¿49 years), with marked variation by country, mainly in post-menopause (50-99 years). Hormonal therapy was given to 55.5% of oestrogen-positive cases, 44.6% at 15-49 years and 58.8% at 50-99 years; with marked variation across countries especially in premenopause. The variation in breast cancer care across Europe prior to the development of European guidelines was striking; older women received BCS + RT much less than younger women; and adherence to "standard care" varied even among countries with medium/high TNEH, suggesting sub-optimal resource allocation.